2017-05-22 14:00
Dr Rotstein received his Ph.D at Karolinska Institutet and has worked as an oncologist for almost 40 years. He was previously Head of Department at the Oncology Clinic at Danderyd Hospital where he together with his colleagues built and managed a highly-appreciated...
2017-05-04 10:00
The value of the order is approximately one million SEK . The order is one of several from the same customer and so far, the second largest Biovica has received. "We are very pleased that leading actors in the industry see the value of our product...
2017-04-11 09:30
Patients in the study are given different standard therapies, meaning that the value of DiviTum® is tested in a significantly larger patient population than what previously has been presented in Biovica breast cancer studies. Results from the study...
2017-04-07 09:00
The drug, a SUMO-ylation inhibitor (SUMOi) developed by the Dutch company UbiQ. Biovica’s DiviTum® technology will be used in pre-clinical models to provide an early signal of cell growth inhibition during development and Biovica’s work...
2017-04-03 17:30
The results, presented as part of an ongoing clinical trial (NCT02022982) at the Dana-Farber Cancer Institute, demonstrate that the DiviTum® assay for determining Thymidine Kinase Activity (TKA) can be a practical, non-invasive tool for monitoring...
2017-02-22 14:30
Cecilia Driving holds a dual degree in BA and law. She has held several CFO positions in life science, private equity, research and telecom companies. Her previous experience includes IPO processes and working in publicly-listed companies. Cecilia is...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects